Adam S. Giermasz, M.D.

Clinics

More about Adam S. Giermasz

Education

University of Warsaw School of Medicine 1998

Residencies

UPMC Montefiore University Hospital 2008

Fellowships

UCSF Medical Center 2011

Selected Research and Publications

1. Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug; 58(8):1329-36.
2. Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8.
3. Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2006; 36(1-3):137-46.
4. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005 Oct; 5(10):1303-15.
5. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005 Feb; 42(4):535-9.
6. Stoklosa T, Golab J, Wójcik C, Wlodarski P, Jalili A, Januszko P, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakóbisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis. 2004 Mar; 9(2):193-204.
7. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003 Sep 1; 171(5):2366-73.
8. O'Connell PJ, Son YI, Giermasz A, Wang Z, Logar AJ, Thomson AW, Kalinski P. Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. Eur J Immunol. 2003 Jul; 33(7):2007-13.
9. Jalili A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J. A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep. 2002 Sep-Oct; 9(5):991-4.
10. Dabrowska-Iwanicka A, Olszewska D, Jalili A, Makowski M, Grzela T, Marczak M, Hoser G, Giermasz A, Golab J, Jakóbisiak M. Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. J Cancer Res Clin Oncol. 2002 Aug; 128(8):433-42.
11. Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A, Jakóbisiak M. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep. 2002 Jul-Aug; 9(4):879-85.
12. Kozar K, Kaminski R, Giermasz A, Basak G, Zagozdzon R, Rybczynska J, Wasik M, Lasek W, Jakobisiak M, Golab J. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. Oncol Rep. 2002 Mar-Apr; 9(2):427-31.
13. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wójcik C, Dabrowska A, Jakóbisiak M, Golab J. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer. 2002 Feb 20; 97(6):746-50.
14. Giermasz A, Makowski M, Nowis D, Jalili A, Maj M, Dabrowska A, Czajka A, Jakobisiak M, Golab J. Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncol Rep. 2002 Jan-Feb; 9(1):199-203.
15. Giermasz A, Grzela T, Nowis D, Makowski M, Czajka A, Stoklosa T, Lasek W, Dabrowsk A, Wiznerowicz M, Mackiewicz A, Jakóbisiak M. Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. Anticancer Res. 2001 Nov-Dec; 21(6A):4001-4.
16. Gol b J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W, Jakóbisiak M. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia. 2001 Apr; 15(4):613-20.
17. Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Mlynarczuk I, Hoser G, Stok osa T, Lewandowski S, Jakóbisiak M. Antitumor activity of tributyrin in murine melanoma model. Cancer Lett. 2001 Mar 26; 164(2):143-8.
18. Dabrowska A, Giermasz A, Golab J, Jakóbisiak M. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma. 2001; 48(5):358-61.
19. Wójcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakóbisiak M. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol. 2000 Sep; 32(9):957-65.
20. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakóbisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res. 2000 May; 6(5):2044-52.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.